Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is clinically necessary. Complete DPD deficiency markedly impairs 5-FU ...
were treated with infused intravenous (IV) 5FU/FA.*(1) The individual trials compared capecitabine with the previous standard IV 5-FU/FA, ...
Metronomic chemotherapy with capecitabine (Xeloda) plus an aromatase inhibitor (AI) could be a first-line treatment option for some patients with HR-positive, HER2-negative metastatic breast cancer, ...
BOSTON (Reuters) - Older breast cancer patients who got Roche AG's drug Xeloda all by itself were almost twice as likely to relapse and die than women who got standard chemotherapy, U.S. researchers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results